Heart Center, Turku University Hospital and University of Turku, Turku, Finland.
Department of Neurology, North Karelia Central Hospital, Siun Sote, Joensuu, Finland; Department of Neurology, University of Turku, Turku, Finland.
Am J Cardiol. 2020 Nov 15;135:17-23. doi: 10.1016/j.amjcard.2020.08.042. Epub 2020 Aug 29.
The objectives of this study were to investigate the outcome differences between ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) patients treated with coronary artery bypass grafting surgery (CABG). We conducted a multicenter, retrospective cohort follow-up study of consecutive patients with STEMI (surgery ≤48 hours of admission; n = 348) or NSTEMI (n = 1,160) revascularized with first-time isolated CABG in Finland using nationwide registries (median age 68 years, 24% women). The short- and long-term (10-year) outcomes were studied with inverse propensity probability weight adjustment for baseline features. The median follow-up was 5.2 years. In-hospital mortality (11.4% vs 5.3%; adj. odds ratio [OR] 2.27; confidence interval [CI] 1.41 to 3.66; p = 0.001) and re-sternotomy rates (6.9% vs 3.5%; adj. OR 2.07; CI 1.22 to 3.51; p = 0.007) were higher in STEMI patients. Long-term all-cause mortality did not differ between STEMI and NSTEMI patients among all operated patients (30.2% vs 28.3%; adj. HR 1.30; CI 0.97 to 1.75; p = 0.080) or hospital survivors (21.6 vs 24.3%; HR 0.93; CI 0.64 to 1.36; p = 0.713). Occurrence of major adverse cardiovascular event in hospital survivors within 10 years was 34.7% in STEMI versus 29.6% in NSTEMI (adj. HR 1.24; CI 0.88 to 1.76; p = 0.220). Occurrences of cardiovascular death (14.6% vs 14.4%; p = 0.773), myocardial infarction (MI; 15.2% vs 10.3%; p = 0.203), and stroke (10.8% vs 14.8%; p = 0.242) were also comparable. In conclusion, patients with STEMI have poorer short-term outcome compared to NSTEMI patients after revascularization by CABG, but the long-term outcomes are comparable regardless of MI type. Thus, both short- and long-term risks should be considered when evaluating patient´s for CABG eligibility by MI type.
本研究旨在探讨经冠状动脉旁路移植术(CABG)治疗的 ST 段抬高型心肌梗死(STEMI)和非 ST 段抬高型心肌梗死(NSTEMI)患者的结局差异。我们使用芬兰全国登记系统,对连续接受首次孤立性 CABG 血运重建的 STEMI(入院后≤48 小时手术;n=348)或 NSTEMI(n=1160)患者进行了一项多中心回顾性队列随访研究(中位年龄 68 岁,24%为女性)。采用逆概率倾向评分调整基线特征进行短期和长期(10 年)结局研究。中位随访时间为 5.2 年。STEMI 患者院内死亡率(11.4%比 5.3%;校正比值比[OR] 2.27;95%置信区间[CI] 1.41 至 3.66;p=0.001)和再次开胸率(6.9%比 3.5%;校正 OR 2.07;95%CI 1.22 至 3.51;p=0.007)更高。在所有接受手术的患者中,STEMI 患者的长期全因死亡率与 NSTEMI 患者无差异(30.2%比 28.3%;校正 HR 1.30;95%CI 0.97 至 1.75;p=0.080)或医院幸存者(21.6%比 24.3%;HR 0.93;95%CI 0.64 至 1.36;p=0.713)。在 10 年内,院内幸存者发生主要不良心血管事件的发生率为 STEMI 患者 34.7%,NSTEMI 患者 29.6%(校正 HR 1.24;95%CI 0.88 至 1.76;p=0.220)。心血管死亡(14.6%比 14.4%;p=0.773)、心肌梗死(15.2%比 10.3%;p=0.203)和卒中(10.8%比 14.8%;p=0.242)的发生率也相似。总之,与 CABG 血运重建后的 NSTEMI 患者相比,STEMI 患者短期预后较差,但无论心肌梗死类型如何,长期结局相当。因此,在评估患者接受 CABG 的资格时,应考虑到 MI 类型的短期和长期风险。